Drug Database
MI

mite allergy vaccine (Dust mite TOL)

✓ Approved

Laboratorios LETI · therapeutic agent

What is mite allergy vaccine?

mite allergy vaccine is a therapeutic agent developed by Laboratorios LETI. It is approved for therapeutic indications via injectable (others) or oral (po) or subcutaneous injection or sublingual (sl)/oral transmucosal.

Drug Profile

Brand NamesDust mite TOL
CompanyLaboratorios LETI
RouteInjectable (Others), Oral (PO), Subcutaneous Injection, Sublingual (SL)/Oral Transmucosal
StatusApproved

Therapeutic Indications

mite allergy vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved

Related Research Articles

PubMedZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2026-10-22

[Effect of the number of sensitizing allergens on the efficacy of subcutaneous immunotherapy and quality of life in children with asthma].

Xu Mo-Yu MY, Wang Yu-Die YD, Liu Jia-Yi JY, Jiang Han H et al.

To compare the efficacy of subcutaneous immunotherapy (SCIT) and its impact on quality of life between children with dust mite-allergic asthma who are monosensitized and those who are polysensitized. This prospective longitudinal cohort study enrolled 80 children with dust mite-allergic asthma, who were divided into a monosensitization group (n=40) and a polysensitization group (n=40). All children completed 3 years of standardized dust mite SCIT. Indicators compared between the two groups before and after treatment included peripheral blood eosinophil percentage, fractional exhaled nitric oxide, pulmonary function parameters, visual analog scale score, Asthma Control Test score, quality of life score, and Children's Sleep Habits Questionnaire score. After 3 years of treatment, both groups showed significant improvements in all indicators from baseline (all P<0.05). The monosensitization group demonstrated greater improvements than the polysensitization group in peripheral blood eosinophil percentage, fractional exhaled nitric oxide, maximum mid-expiratory flow as a percentage of predicted value, Asthma Control Test scores, and quality of life scores (all P<0.05). The incidence of adverse reactions did not differ significantly between the two groups (P>0.05). SCIT is effective in children with dust mite-allergic asthma, and monosensitized children show greater improvements in small airway function, asthma control, and quality of life.

PubMedBulletin of entomological research2026-10-22

Effects of a short-term heat stress on the functional response of Scolothrips longicornis to Tetranychus urticae.

Pakyari Hajar H

Biological control employing predatory insects represents an environmentally sustainable approach for suppressing two-spotted spider mite populations in both greenhouse and open-field cropping systems. In the present study, a laboratory experiment was performed to assess the functional response and predation efficiency of the predatory thrips Scolothrips longicornis (Thysanoptera: Thripidae) feeding on eggs of the two-spotted spider mite, Tetranychus urticae (Acari: Tetranychidae), with particular emphasis on the influence of short-term heat stress. Functional response assays were conducted over a 24-h period under three temperature regimes (38°C, 40°C, and 42°C), three durations of short-term heat exposure (2, 4, and 6 h), seven prey densities (10, 20, 30, 40, 50, 60, and 70 individuals), a relative humidity of 60 ± 10%, and a 16:8 h (L:D) photoperiod. The results showed that S. longicornis eggs failed to hatch at 42°C. Logistic regression analysis further revealed that adult females of S. longicornis exhibited a type II functional response under all experimental treatments. The highest attack rate on T. urticae eggs was recorded at 25°C (0.0506 h-1), whereas the lowest value (0.0367 h-1) occurred following exposure to 40°C for 6 h. In contrast, handling time increased progressively with rising temperature from 25°C to 40°C, reaching its maximum at 40°C after 6 h of heat exposure (1.1467 h). These findings indicate that short-term heat stress adversely affects the predatory performance of S. longicornis. Therefore, exposure to heat stress should be minimised to maximise its predation efficiency and biological control effectiveness during both mass rearing and field release.

PubMedFrontiers in immunology2026-10-22

A subunit vaccine protects A129 mice from death and joint swelling against lethal Chikungunya virus challenge.

Li Jiangfan J, Fang Ting T, Song Liyuan L, Qiang Li L et al.

Chikungunya virus (CHIKV) is primarily transmitted to humans through bites of infected Aedes mosquitoes, causing febrile illness as well as acute or chronic arthritis. With increasing reports in previously non-endemic regions, it poses an emerging threat to public health and a growing risk to travelers. Despite the recent approval of live-attenuated and virus-like particle-based vaccines, a safe, efficacious, and cost-effective vaccine remains urgently needed. The envelope glycoproteins E1 and E2, which play crucial roles in viral attachment and entry, are the major immunodominant structural proteins and can effectively elicit protective antibodies. We engineered mammalian cells to produce the ectodomains of the E1 and E2 glycoproteins and evaluated the protective efficacy of the resulting vaccine formulations in vivo. A two-dose vaccination regimen elicited high levels of antibodies and provided full protection against lethal challenge in A129 mice, preventing both death and joint swelling. These findings demonstrate the potential of this vaccine candidate against CHIKV and warrant its further development.

PubMedEpidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil2026-10-22

[Strategies to address vaccine hesitancy in Brazil: evidence synthesis].

Marques Ana Paula da Costa APDC, Gubert Vanessa Terezinha VT, Dias Adriano da Costa ADC, Gasparoto Antonio Luiz Dal Bello ALDB et al.

PubMedZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2026-10-22

[Expression patterns of fecal iron metabolism-related proteins in infants with food allergy].

Zhou Zi-Bei ZB, Zhang Juan J, Li Zai-Ling ZL

To investigate the expression patterns of fecal iron metabolism-related proteins at the early stage of food allergy (FA) onset in infants, and to explore the association between imbalance of local intestinal iron homeostasis and infant FA. A nested case-control design within a prospective clinical cohort was used. From October 2024 to June 2025, 162 infants with suspected FA were recruited from outpatient clinics, the child health department, and community settings, and classified into an FA group (n=88) and a non-FA group (n=74) according to standardized oral food challenge results. Baseline fecal samples collected prior to diagnosis were tested by enzyme-linked immunosorbent assay for iron metabolism-related proteins, and fecal non-heme iron content was measured. Group differences were compared. FA onset peaked at 4-6 months of age, coinciding with the period of physiological depletion of fetal iron stores. Gastrointestinal symptoms predominated. Compared with the non-FA group, the FA group had significantly higher fecal transferrin receptor 1 concentrations (P<0.001) and significantly lower ferritin heavy chain, ferritin light chain, and non-heme iron content (all P<0.05). No significant between-group differences were observed in lactoferrin or hephaestin concentrations (P>0.05). Infants with FA exhibit an imbalance of local intestinal iron homeostasis at the early stage of disease onset, characterized by enhanced iron uptake signaling alongside reduced iron storage, indicative of a functional iron deficiency state. This imbalance appears associated with the early occurrence of infant FA.

PubMedKidney research and clinical practice2026-10-22

Clinical effects of third doses of mRNA COVID-19 vaccines among hemodialysis patients: a nationwide retrospective cohort study.

Cho AJin A, Jeong Seon A SA, Seo Yu Bin YB, Park Hayne Cho HC et al.

Evidence on the effectiveness of third-dose messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccination during the Omicron-dominant period in Asian hemodialysis (HD) patients remains limited. We evaluated the clinical effectiveness of a third mRNA vaccine dose against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospitalization, and mortality in Korean HD patients. Using the Korea Disease Control and Prevention Agency-National Health Insurance Service database, we conducted a nationwide cohort study of HD patients aged ≥18 years who received two or three doses of BNT162b2 or mRNA-1273 before January 16, 2022. Study outcomes were SARS-CoV-2 infection, hospitalization, and death. Cox proportional hazards models were used to assess the associations between third-dose vaccination and clinical outcomes. Among 66,389 HD patients (mean age, 65.7 ± 12.9 years; 60.5% male), 55,125 (83.0%) received three vaccine doses and 11,264 (17.0%) received two doses. Receipt of three doses was associated with a significantly lower risk of SARS-CoV-2 infection (adjusted hazard ratio [aHR], 0.58; 95% confidence interval [CI], 0.56-0.60). Among 17,886 patients with SARS-CoV-2 infection, third-dose vaccine recipients had a lower risk of hospitalization (aHR, 0.65; 95% CI, 0.62-0.70) and 30-day mortality (aHR, 0.35; 95% CI, 0.30-0.41) compared with those who received two doses. Receipt of mRNA-1273 as the third dose was associated with lower observed risks of infection and hospitalization than receipt of BNT162b2. A third dose of an mRNA COVID-19 vaccine was associated with lower risks of SARS-CoV-2 infection, hospitalization, and mortality among HD patients during the Omicron-dominant period. These findings support the clinical importance of booster vaccination in this high-risk population.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about mite allergy vaccine